Drug Profile

OKL 1111

Alternative Names: OKL-1111

Latest Information Update: 04 Mar 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Okklo Life Sciences - Prothya BioSolutions (JV); Sanquin Blood Supply Foundation
Developer Alveron Pharma
Class Antihaemorrhagics; Cyclodextrins
Mechanism of Action Blood coagulation factor inhibitors; Platelet aggregation inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Phase I Haemorrhage

Most Recent Events

02 Oct 2023 Alveron Pharma completes a phase I clinical trials in Haemorrhage in United Kingdom (Injection)
20 Mar 2023 Phase-I clinical trials in Haemorrhage in United Kingdom (Injection)
01 May 2019 Okklo Life Sciences and Sanquin Blood Supply Foundation establish a joint venture, known as Alveron Pharma, in May 2019 (Alveron Pharma website, July 2021)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com